Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lydia Roy

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
Blood Cancer Journal|October 6, 2018
Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivoEmmanuelle Verger, Juliette Soret-Dulphy, Nabih Maslah, et al.
Scientific Reports|May 3, 2022
Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance databaseLéa Hoisnard, Bénédicte Lebrun-Vignes, Sébastien Maury, et al.
The Journal of Molecular Diagnostics : JMD|August 13, 2022
Fusion Gene Detection and Quantification by Asymmetric Capture Sequencing (aCAP-Seq)Guillaume Gricourt, Violaine Tran Quang, Jean-Michel Cayuela, et al.
Cancer Immunology, Immunotherapy : CII|December 19, 2025
Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patientsEmilie Cayssials, Lucie Lefèvre, Amandine Decroos, et al.
Annales De Pathologie|September 1, 2022
[Myeloid neoplasms associated with rearrangement of PDGFRB: A rare and tricky disease]Christophe Bontoux, Bouchra Badaoui, Nassera Abermil, et al.
Cancer Research|March 29, 2014
BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patientsAnaïs Levescot, Stéphane Flamant, Sara Basbous, et al.
Cancer|May 28, 2020
Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective studyEmilie Cayssials, Jose Torregrosa-Diaz, Pilar Gallego-Hernanz, et al.
Experimental Hematology|September 9, 2018
Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational studyMaël Heiblig, Delphine Rea, Marie-Lorraine Chrétien, et al.
Cancer|December 28, 2016
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept studyPhilippe Rousselot, Stéphane Prost, Joelle Guilhot, et al.
Leukemia|January 26, 2024
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trialHjalmar Flygt, Stina Söderlund, Johan Richter, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Blood Cancer Journal|October 6, 2018
Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivoEmmanuelle Verger, Juliette Soret-Dulphy, Nabih Maslah, et al.
Scientific Reports|May 3, 2022
Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance databaseLéa Hoisnard, Bénédicte Lebrun-Vignes, Sébastien Maury, et al.
The Journal of Molecular Diagnostics : JMD|August 13, 2022
Fusion Gene Detection and Quantification by Asymmetric Capture Sequencing (aCAP-Seq)Guillaume Gricourt, Violaine Tran Quang, Jean-Michel Cayuela, et al.
Cancer Immunology, Immunotherapy : CII|December 19, 2025
Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patientsEmilie Cayssials, Lucie Lefèvre, Amandine Decroos, et al.
Annales De Pathologie|September 1, 2022
[Myeloid neoplasms associated with rearrangement of PDGFRB: A rare and tricky disease]Christophe Bontoux, Bouchra Badaoui, Nassera Abermil, et al.
Cancer Research|March 29, 2014
BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patientsAnaïs Levescot, Stéphane Flamant, Sara Basbous, et al.
Cancer|May 28, 2020
Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective studyEmilie Cayssials, Jose Torregrosa-Diaz, Pilar Gallego-Hernanz, et al.
Experimental Hematology|September 9, 2018
Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational studyMaël Heiblig, Delphine Rea, Marie-Lorraine Chrétien, et al.
Cancer|December 28, 2016
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept studyPhilippe Rousselot, Stéphane Prost, Joelle Guilhot, et al.
Leukemia|January 26, 2024
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trialHjalmar Flygt, Stina Söderlund, Johan Richter, et al.
Pageof 7